AM Biotech scientists are experts with decades of experience working with nucleic acids and X-Aptamers. The company not only provides unique services and products to customers but also is actively involved in research to improve aptamer performance. Our scientists continue to publish in respected journals, such as Nature and Nucleic Acid Research, not only about aptamer markets and technology reviews, but on significant advances in understanding X-Aptamer technology and performance.

The result of the expertise and novel research performed by AM Biotech’s scientists are X-Aptamers: short strands of chemically modified nucleic acids that bind to targets with high affinity and specificity. Unlike outdated aptamers and antibodies, identifying X-Aptamers is a fast and easy method done with a unique X-Aptamer selection kit. AM Biotech’s mission is to lower the barriers for new users to try synthetic affinity reagents. X-Aptamer selection kits resolve both the lack of available synthetic affinity molecules that new users can purchase from a catalog and the high cost to develop synthetic affinity agents.

AM Biotech has eliminated the cost barrier using a unique, Co-Development option. Customers purchase our inexpensive kit and complete the protocol using several targets of their choice. AM Biotech will process the sample that results from the kit and deliver several X-Aptamers to test for no charge in exchange for a non-exclusive license to sell the X-Aptamers. Customers benefit from fast, affordable development of excellent synthetic affinity molecules of interest to them. AM Biotech benefits by monetizing the X-Aptamers through an ecommerce catalog. Customers are completely free to commercialize the X-Aptamers they developed and even have the potential to earn a royalty from AM Biotech on catalog sales of X-Aptamers that they developed using the kit.

AM Biotech also offers a turnkey service for selecting X-Aptamers to customer provided targets and will improve existing aptamers (and siRNA) using unique chemical modifications. Reagents used to synthesize some of the unique chemical modifications can be purchased through AM Biotech.

AM Biotech is located in Houston, Texas, southeast of the Texas Medical Center. It has been in operation since 2006, developing chemically modified aptamers using a version of a combinatorial chemistry technology originally developed at the University of Texas Medical Branch in Galveston, Texas.

AM Biotech Customers Include:

  • Major pharmaceutical companies (US and Europe)
  • Biotechnology companies (US and Europe)
  • Universities (US and Canada)
  • The National Institutes of Health (NIH)
  • The National Aeronautics and Space Administration (NASA)
  • The UK Defence Science & Technology Laboratory (DSTL)

X-Aptamer Selection Kit Distributors:

  • Japan – Funakoshi
  • South Korea – Sambo

The following entities have generously provided support for research:

  • The National Institutes of Health (NIH)
  • The National Aeronautics and Space Administration (NASA)
  • Defense Advanced Research Projects Agency (DARPA)
  • The Bill & Melinda Gates Foundation

World Map of AM Biotech Customers and Distributors: